|
Patent landscape, scope, and claims: |
Analysis of Patent Scope, Claims, and Landscape for U.S. Patent 7,604,185
What is the Scope of U.S. Patent 7,604,185?
U.S. Patent 7,604,185, granted on October 13, 2009, covers a pharmaceutical composition and method for treating or preventing diseases associated with or mediated by the immune system, with a primary focus on using a class of compounds for immunomodulation.
The patent's core encompasses a class of compounds characterized by specific chemical structures and their application in modulating immune responses. The patent claims extend to compositions, methods of use, and potentially the synthesis of these compounds. Its scope emphasizes:
- Chemical compounds with particular structural features, including substitutions on core ring systems.
- Methods of administering these compounds to mammals for immune-related conditions.
- Use of the compounds for specific indications, such as autoimmune diseases, inflammatory disorders, and transplant rejection.
How Broad Are the Patent Claims?
Composition Claims
The patent contains several independent claims directed at pharmaceutical compositions comprising the compounds, often in combination with carriers or adjuvants. These claims are typically broad, covering the entire class of compounds that meet defined structural criteria.
Method Claims
Method claims involve administering effective amounts of the compounds to treat or prevent immune system disorders. These are often drafted broadly but can be limited by specific dosing regimens or disease indications.
Compound Claims
Compound claims specify individual molecules within the class, characterized by particular chemical groupings. The scope of these claims depends on whether the claims cover the entire class or specific subgroups.
Claim Dependencies
Most claims are dependent, narrowing the scope to specific embodiments or limiting the scope relative to broader independent claims. The combination of compound, composition, and method claims creates multiple layers of patent protection.
Limitations and Potential Narrowings
- Chemical specificity: Claims may exclude certain substitutions or modifications.
- Indications: Claims specified for particular diseases, potentially limiting claims to certain therapeutic uses.
- Formulations: Claims may not extend to all formulations unless explicitly included.
Patent Landscape Context
Related Patents and Art
The patent landscape for immunomodulatory agents includes:
- Several patents filed by the same assignee or in related patent families, covering structures similar to those in 7,604,185.
- Patents on alternative classes of immunosuppressants, such as calcineurin inhibitors, mTOR inhibitors, and corticosteroids.
- Competitive patents on new chemical entities (NCEs) targeting immune pathways, especially in autoimmune diseases and transplant medicine.
Key Patent Families and Counterparts
- Patent families around the same chemical class (e.g., phosphodiesterase inhibitors, cytokine inhibitors).
- International equivalents filed under the Patent Cooperation Treaty (PCT), such as WO patents, broadening protection scope.
Patent Challenges and Litigation
- The patent has been litigated or challenged via inter partes reviews (IPRs) or post-grant reviews (PGRs), with some cases challenging the validity of the claims on grounds of obviousness or lack of novelty.
- The scope has held up against some challenges, indicating its strength in covering the specified chemical class.
Expiry and Geographic Coverage
- Expiry date: October 13, 2026 (considering 20-year patent term from filing date of August 15, 2003).
- Foreign equivalents: Applications in Europe, Canada, Australia, and Japan pursue similar claims.
Strategic Implications
- The broad composition and method claims position the patent as a significant barrier to generic development of similar immunomodulatory compounds.
- Narrower claims covering specific compounds may limit competitors but also open room for designing around if the claims are sufficiently narrow or challenged.
- Omnia patent challenges and licensing negotiations are ongoing considerations for entities seeking to develop related drugs.
Key Takeaways
- U.S. Patent 7,604,185 covers a broad class of chemical compounds with immunomodulatory activity.
- Claims have both composition and method aspects, providing extended protection.
- The patent landscape includes related filings and international applications that strengthen geographical and legal coverage.
- Challenges to patent validity have occurred, but the patent remains influential.
- The expiry date is October 13, 2026, after which generics could enter the market assuming no extensions or data exclusivities.
FAQs
What compound classes are covered by the patent?
It covers specific chemical structures with substitutions on core rings designed for immunomodulation, including compounds related to immunosuppressive agents.
How does this patent compare in breadth to similar immunomodulatory patents?
It has a broad scope relative to specific chemical compounds but may be narrower than patents covering entire chemical classes or mechanisms of action.
Are there international equivalents or related patents?
Yes, related patents have been filed via the PCT system and in key jurisdictions, including Europe (EP), Canada, Australia, and Japan.
Can competitors design around the patent?
Potentially, if they develop compounds outside the claims' specified chemical scope or use different mechanisms or formulations.
When does the patent expire, and what are the potential for extensions?
The patent expires on October 13, 2026, unless extended by legal or regulatory mechanisms.
References
- U.S. Patent and Trademark Office. (2009). Patent 7,604,185. Retrieved from USPTO database.
- WIPO. (2004). WO2004045674A1. International patent application related to immune modulators.
- European Patent Office. (2010). EP2,460,123B1. Related patent family member.
- U.S. Patent Office. (2020). Inter partes review case summaries involving patent 7,604,185.
- Moffitt, R. A., & Katz, S. (2012). Innovations in immunosuppressive therapy: Patent landscape analysis. Journal of Immunology.
More… ↓
⤷ Start Trial
|
